Welcome, Guest. Please login or register.
April 25, 2024, 12:36:37 am

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 106
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 82
Total: 82

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Hep C Reinfection Rate Is Low After Zepatier Cures Opioid Addicts  (Read 5195 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
After Zepatier (grazoprevir/elbasvir) cured a high rate of individuals addicted to opioids of hepatitis C virus (HCV), few became reinfected during a large study’s long-term follow-up period, aidsmap reports.

Researchers from the multinational Zepatier Phase III C-EDGE CO-STAR study presented long-term follow-up data at the 25th International Harm Reduction Conference (HR17) in Montreal. The initial phase of the study included 301 first-timers to hep C treatment with genotypes 1, 4 or 6 of the virus. All had been taking opioid substitution therapy, including methadone or buprenorphine, for at least three months prior to entering the study. All were given 12 weeks of Zepatier.

Read more...
https://www.hepmag.com/article/hep-c-reinfection-rate-low-zepatier-cures-opioid-addicts

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.